间质性肺疾病合并肺癌的临床分析(4)
[5] 赵静， 刘瑞娟. 血清CEA、CYFR21-1、NSE检测在特发性肺间质纤维化合并肺癌中的临床意义. 济南大学， 2014.
[6] 王玉超， 杨晓红， 邬超. 特发性肺纤维化合并肺癌患者血清肿瘤标志物CEA、CA199、CA125、CA153檢测分析. 山东医药， 2013， 53(29)：78-79.
[7] Sato T， Watanabe A， Kondo H， et al. Long-term results and predictors of survival after surgical resection of patient with lung cancer and interstitial lung disease. J Thorac Cardiovasc Surg， 2015(149)：64-69.
[8] Luca Voltolini. Stefano Bongiolatti.Luca Luzzi， et al. Impact of interstitⅠal lung disease on short-term and long-term survival of patients undergoing surgery for non-small-cell lung cancer：analysis of risk factors. Eur J Cardiothorac Surg， 2013(43)：17-23.
[9] Gridelli C， Morgillo F， Favaretto A， et al. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small cell lung cancer：a randomized phase II study. Ann Oncol， 2011， 22(7)：1528-1534.
[10] Bauman JE， Eaton KD， Wallace SG， et al. A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer. BMC Cancer， 2012， 12(1)：449.
[11] Kanal O， Kim YH， Demura Y. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thorac Cancer， 2018， 9(7)：847-855.
[收稿日期：2020-02-26], http://www.100md.com(古丽 聂洪玉 孙楷)
[6] 王玉超， 杨晓红， 邬超. 特发性肺纤维化合并肺癌患者血清肿瘤标志物CEA、CA199、CA125、CA153檢测分析. 山东医药， 2013， 53(29)：78-79.
[7] Sato T， Watanabe A， Kondo H， et al. Long-term results and predictors of survival after surgical resection of patient with lung cancer and interstitial lung disease. J Thorac Cardiovasc Surg， 2015(149)：64-69.
[8] Luca Voltolini. Stefano Bongiolatti.Luca Luzzi， et al. Impact of interstitⅠal lung disease on short-term and long-term survival of patients undergoing surgery for non-small-cell lung cancer：analysis of risk factors. Eur J Cardiothorac Surg， 2013(43)：17-23.
[9] Gridelli C， Morgillo F， Favaretto A， et al. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small cell lung cancer：a randomized phase II study. Ann Oncol， 2011， 22(7)：1528-1534.
[10] Bauman JE， Eaton KD， Wallace SG， et al. A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer. BMC Cancer， 2012， 12(1)：449.
[11] Kanal O， Kim YH， Demura Y. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thorac Cancer， 2018， 9(7)：847-855.
[收稿日期：2020-02-26], http://www.100md.com(古丽 聂洪玉 孙楷)